Clinical Trial Update: Alpha-Galactosidase A Replacement Therapy for Fabry Disease [Phase 2]

View source ↗

Summary

A Phase 2 trial of Alpha-Galactosidase A replacement therapy for Fabry disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fabry Disease

Drugs mentioned

• Alpha-Galactosidase A (alpha-galactosidase A)

Snippet

Sponsor: National Institute of Neurological Disorders and Stroke (NINDS) | Conditions: Fabry Disease | Phase 2 | Status: COMPLETED